Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of DLX 1 for CNS-disorders

Next Previous
X
Search
Trial Profile

A clinical trial of DLX 1 for CNS-disorders

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DLX-1 (Primary)
  • Indications CNS disorders; Major depressive disorder
  • Focus Adverse reactions; First in man; Pharmacokinetics

    • Most Recent Events

    • 13 May 2024 Results published in a Delix Therapeutics media release
    • 13 May 2024 According to a Delix Therapeutics media release, data from this trial will be presented at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting from May 28-31 in Miami Beach, Florida.
    • 13 May 2024 According to a Delix Therapeutics media release, today announced additional data from ongoing Phase 1 trial evaluating DLX-001, demonstrating evidence of brain activity in healthy volunteers without producing psychotomimetic, dissociative or hallucinogenic effects. These data were presented at the 2024 Society of Biological Psychiatry (SOBP) Annual Meeting from May 9-11 in Austin, Texas.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top